<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01695408</url>
  </required_header>
  <id_info>
    <org_study_id>INSIGHTS-IPF</org_study_id>
    <nct_id>NCT01695408</nct_id>
  </id_info>
  <brief_title>Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>INSIGHTS-IPF</acronym>
  <official_title>Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing
      interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the mean
      survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years. As in
      Europe data are limited on the characteristics and management of such patients, INSIGHTS-IPF
      was initiated as a new registry that documents newly diagnosed (incident) and prevalent
      patients with confirmed IPF diagnosis prospectively.The registry will contribute to the
      optimization of the management of IPF patients in the long term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INSIGHTS-IPF will report current and comprehensive data on Idiopathic Pulmonary Fibrosis
      (IPF) in the long-term.

      Baseline (cross-sectional part): Description of characteristics of IPF patients in terms of

        -  key (socio-) demographic data

        -  IPF risk factors, comorbidities

        -  methods used for IPF diagnosis

        -  IPF disease severity and manifestation (including lung function, cardiopulmonary
           exercise testing and/or exercise capacity if available, laboratory values, biomarkers)

        -  IPF treatment (detailed information on prescribed drugs and doses; non-pharmacological
           treatment; listing and score for lung transplantation)

        -  assessment of patient-related outcomes (PRO) such as quality of life

      Follow-up (prospectively up to at least 2 years after inclusion):

        -  Clinical course of IPF (e.g. in terms of symptoms, lung function, exercise capacity if
           available)

        -  Documentation of treatment pathways (switch/add-on/discontinuation of medication), and
           of non-pharmacological treatment (e.g. start of long term oxygen therapy; new listing
           for lung transplantation)Outcomes/events (such as acute respiratory worsening,
           exacerbations, hospitalisation due to any cause and due to IPF, other complications,
           survival)

        -  Patient-related outcomes such as quality of life, assessed once a year(for comparison
           with baseline)

        -  Resource use for pharmacoeconomic analyses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical course of IPF (in terms of symptoms, lung function, survival)</measure>
    <time_frame>up to 4 years after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics of patients with IPF</measure>
    <time_frame>up to 4 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment pathways</measure>
    <time_frame>up to 4 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality and quality of life</measure>
    <time_frame>up to 4 years after inclusion</time_frame>
    <description>St. Georges Respiratory Questionnaire; University of California Shortness of Breath Questionnaire; EuroQuol 5 dimensions</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Idiopathic Pulmonary Fibrosis (confirmed diagnosis according to current
        ATS/ERS guidelines)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Written informed consent for participation in the registry

          -  Newly diagnosed (incident) or known (prevalent) IPF (based on diagnosis of treating
             physician)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Behr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Fachkliniken München Gauting Medizinischen Klinik und Poliklinik V Klinikum der Ludwig-Maximilians-Universität München Comprehensive Pneumology Center Munich (CPC-M) Mitglied des Deutschen Zentrums für Lungenforschung (DZL)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Pittrow, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Behr, MD</last_name>
    <phone>089 85791</phone>
    <phone_ext>4101</phone_ext>
    <email>j.behr@asklepios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Pittrow, MD, PhD</last_name>
    <phone>+49 351 25933</phone>
    <phone_ext>182</phone_ext>
    <email>david.pittrow@mailbox.tu-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Clinical Pharmacology, Medical Faculty, Technical University</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Pneumologie, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Prasse, MD</last_name>
      <phone>+49511 532</phone>
      <phone_ext>3934</phone_ext>
      <email>pneumologie@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Antje Prasse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pneumologie und Beatmungsmedizin, Thoraxklinik,Universitätsklinikum</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kreuter, MD</last_name>
      <phone>+496221396</phone>
      <phone_ext>1214</phone_ext>
      <email>michael.kreuter@thoraxklinik-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kreuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abteilung für Pneumologie Department Innere Medizin, Neurologie und Dermatologie Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Wirtz, MD</last_name>
      <email>hubert.wirtz@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Hubert Wirtz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>V. Med. Clinic, Ludwig-Maximilians-Unviversity</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Behr, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://insights-ipf.de</url>
    <description>Study website</description>
  </link>
  <reference>
    <citation>Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D. [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8. doi: 10.1055/s-0032-1327244. Epub 2012 Nov 27. Review. German.</citation>
    <PMID>23188642</PMID>
  </reference>
  <reference>
    <citation>Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D. Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res. 2014 Jan 3;1(1):e000010. doi: 10.1136/bmjresp-2013-000010. eCollection 2014. Erratum in: BMJ Open Respir Res. 2014;1(1):e000010corr1.</citation>
    <PMID>25478169</PMID>
  </reference>
  <results_reference>
    <citation>Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Randerath W, Skowasch D, Meyer FJ, Kirschner J, Gläser S, Herth FJ, Welte T, Huber RM, Neurohr C, Schwaiblmair M, Kohlhäufl M, Höffken G, Held M, Koch A, Bahmer T, Pittrow D. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015 Jul;46(1):186-96. doi: 10.1183/09031936.00217614. Epub 2015 Apr 2.</citation>
    <PMID>25837040</PMID>
  </results_reference>
  <results_reference>
    <citation>Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Herth FJF, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Frankenberger M, Behr J. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017 Jul 14;18(1):139. doi: 10.1186/s12931-017-0621-y.</citation>
    <PMID>28709421</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2012</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Treatment</keyword>
  <keyword>Treatment pathways</keyword>
  <keyword>Clinical routine</keyword>
  <keyword>Registry</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Survival</keyword>
  <keyword>Patient-related outcomes</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Steroids</keyword>
  <keyword>Azathioprine</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>Pirfenidone</keyword>
  <keyword>Tyrosine kinase inhibitors</keyword>
  <keyword>Nintedanib</keyword>
  <keyword>multicenter</keyword>
  <keyword>Germany</keyword>
  <keyword>Safety</keyword>
  <keyword>Adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

